{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["207(3)"],"submitter":["Johnstone P"],"pubmed_abstract":["Large-cell transformation of mycosis fungoides (LCTMF) is rare, histologically distinct, with an aggressive clinical course; yet is not recognised as an independent entity in classification systems nor in staging systems for mycosis fungoides and Sézary syndrome (MF/SS). Herein, the patterns of care and survival outcomes for patients with LCTMF are described, with prognosis compared to published data of non-transformed MF/SS. Eligibility required clinicopathological diagnosis of LCTMF (1/1/1990-31/10/2021), managed at Peter MacCallum Cancer Centre. Eighty-three patients were eligible. Median follow-up was 8.0 years. At the time of LCTMF, 36% had early-stage MF (IA-IIA), 76% had cutaneous-only LCTMF. The most common first-line treatments were localised radiotherapy (48%) and multiagent chem"],"journal":["British journal of haematology"],"pagination":["824-833"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12436213"],"repository":["biostudies-literature"],"pubmed_title":["Large-cell transformation of mycosis fungoides: Patterns of care and patient outcomes."],"pmcid":["PMC12436213"],"pubmed_authors":["Higgins M","Prince HM","van der Weyden C","Blombery P","McCormack C","Bhabha F","Johnstone P","Buelens O","Campbell BA","Lade S"],"additional_accession":[]},"is_claimable":false,"name":"Large-cell transformation of mycosis fungoides: Patterns of care and patient outcomes.","description":"Large-cell transformation of mycosis fungoides (LCTMF) is rare, histologically distinct, with an aggressive clinical course; yet is not recognised as an independent entity in classification systems nor in staging systems for mycosis fungoides and Sézary syndrome (MF/SS). Herein, the patterns of care and survival outcomes for patients with LCTMF are described, with prognosis compared to published data of non-transformed MF/SS. Eligibility required clinicopathological diagnosis of LCTMF (1/1/1990-31/10/2021), managed at Peter MacCallum Cancer Centre. Eighty-three patients were eligible. Median follow-up was 8.0 years. At the time of LCTMF, 36% had early-stage MF (IA-IIA), 76% had cutaneous-only LCTMF. The most common first-line treatments were localised radiotherapy (48%) and multiagent chem","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-01T14:01:40.446Z","creation":"2026-04-08T13:17:54.402Z"},"accession":"S-EPMC12436213","cross_references":{"pubmed":["40557623"],"doi":["10.1111/bjh.20225"]}}